The hepatic cirrhosis market has been comprehensively analyzed in this report titled "Hepatic Cirrhosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2034". Hepatic cirrhosis is a chronic liver condition characterized by the irreversible scarring of liver tissue, resulting in impaired liver function. This scarring disrupts the normal structure of the liver, replacing healthy tissue with fibrous bands. Common causes include chronic alcohol abuse, viral hepatitis, and fatty liver disease. As the ailment progresses, symptoms may manifest, including fatigue, weakness, abdominal pain, and unintended weight loss. Additionally, individuals suffering from this illness may experience complications such as ascites (fluid buildup in the abdomen), jaundice, and easy bruising or bleeding due to decreased production of clotting factors. Diagnosing hepatic cirrhosis often involves a combination of medical history review, physical examination, and diagnostic tests such as liver function tests, imaging studies (like ultrasound or CT scans), and sometimes a liver biopsy to assess the extent of liver damage.
The escalating incidence of somatic mutations, which contribute to the progressive overgrowth of fibrous tissue in the liver, disrupting its normal function, is primarily driving the hepatic cirrhosis market. In addition to this, the inflating utilization of effective medications, such as antifibrotic agents, diuretics, and beta-blockers, aimed at managing the condition and averting further hepatic damage is creating a positive outlook for the market. Moreover, the widespread adoption of physical and occupational therapies is also bolstering the market growth. These therapeutic interventions not only bolster muscular strength but also enhance coordination and improve gross motor skills in individuals suffering from the ailment. Apart from this, the rising usage of advanced procedures, including transjugular intrahepatic portosystemic shunt (TIPS) and liver transplantation, which aim to alleviate symptoms, reduce complications, and enhance the overall quality of life is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy that involves the introduction of functional genetic material to rectify or replace mutated genes responsible for the underlying condition is expected to drive the hepatic cirrhosis market during the forecast period.
This report provides an exhaustive analysis of the hepatic cirrhosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hepatic cirrhosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hepatic cirrhosis market in any manner.
The escalating incidence of somatic mutations, which contribute to the progressive overgrowth of fibrous tissue in the liver, disrupting its normal function, is primarily driving the hepatic cirrhosis market. In addition to this, the inflating utilization of effective medications, such as antifibrotic agents, diuretics, and beta-blockers, aimed at managing the condition and averting further hepatic damage is creating a positive outlook for the market. Moreover, the widespread adoption of physical and occupational therapies is also bolstering the market growth. These therapeutic interventions not only bolster muscular strength but also enhance coordination and improve gross motor skills in individuals suffering from the ailment. Apart from this, the rising usage of advanced procedures, including transjugular intrahepatic portosystemic shunt (TIPS) and liver transplantation, which aim to alleviate symptoms, reduce complications, and enhance the overall quality of life is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy that involves the introduction of functional genetic material to rectify or replace mutated genes responsible for the underlying condition is expected to drive the hepatic cirrhosis market during the forecast period.
This report provides an exhaustive analysis of the hepatic cirrhosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hepatic cirrhosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hepatic cirrhosis market in any manner.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the hepatic cirrhosis market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the hepatic cirrhosis market
Competitive Landscape:
This report also provides a detailed analysis of the current hepatic cirrhosis marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the hepatic cirrhosis market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the hepatic cirrhosis market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the hepatic cirrhosis market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of hepatic cirrhosis across the seven major markets?
- What is the number of prevalent cases (2018-2034) of hepatic cirrhosis by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of hepatic cirrhosis by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with hepatic cirrhosis across the seven major markets?
- What is the size of the hepatic cirrhosis patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of hepatic cirrhosis?
- What will be the growth rate of patients across the seven major markets?
Hepatic Cirrhosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for hepatic cirrhosis drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hepatic cirrhosis market?
- What are the key regulatory events related to the hepatic cirrhosis market?
- What is the structure of clinical trial landscape by status related to the hepatic cirrhosis market?
- What is the structure of clinical trial landscape by phase related to the hepatic cirrhosis market?
- What is the structure of clinical trial landscape by route of administration related to the hepatic cirrhosis market?
Table of Contents
1 Preface3 Executive Summary6 Patient Journey9 Hepatic Cirrhosis - Unmet Needs10 Hepatic Cirrhosis - Key Endpoints of Treatment13 Hepatic Cirrhosis - Attribute Analysis of Key Marketed and Pipeline Drugs16 Hepatic Cirrhosis - Recent Events and Inputs From Key Opinion Leaders18 Hepatic Cirrhosis Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Hepatic Cirrhosis - Introduction
5 Hepatic Cirrhosis - Disease Overview
7 Hepatic Cirrhosis - Epidemiology and Patient Population
8 Hepatic Cirrhosis - Treatment Algorithm, Guidelines, and Medical Practices
11 Hepatic Cirrhosis - Marketed Products
12 Hepatic Cirrhosis - Pipeline Drugs
14 Hepatic Cirrhosis - Clinical Trial Landscape
15 Hepatic Cirrhosis - Market Scenario
17 Hepatic Cirrhosis Market - SWOT Analysis
Methodology
LOADING...
